Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|November 6, 2018
Treatment-free remission with first- and second-generation tyrosine kinase inhibitorsJorge Cortes, Delphine Rea, Jeffrey H Lipton
European Journal of Haematology|May 7, 2014
Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcomeTristan Mirault, Delphine Rea, Arshid Azarine, et al.
Methods in Molecular Medicine|December 9, 2004
Adenoviral transduction of dendritic cellsRienk Offringa, Kitty Kwappenberg, Martijn Rabelink, et al.
Current Hematologic Malignancy Reports|March 14, 2012
Curing chronic myeloid leukemiaDelphine Rea, Philippe Rousselot, Joelle Guilhot, et al.
Current Hematologic Malignancy Reports|February 23, 2024
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New DirectionsDelphine Rea, Sofiane Fodil, Etienne Lengline, et al.
Lancet (London, England)|September 2, 2008
Dasatinib-induced lupusDelphine Rea, Anne Bergeron, Claire Fieschi, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 13, 2023
Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid LeukemiaSimone E Dekker, Delphine Rea, Jean-Michel Cayuela, et al.
Blood|December 20, 2014
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsPeter Valent, Emir Hadzijusufovic, Gerit-Holger Schernthaner, et al.
Leukemia Research|February 28, 2012
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemiaAdam Gater, Louise Heron, Linda Abetz-Webb, et al.
Haematologica|March 25, 2014
Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemiaDelphine Rea, Tristan Mirault, Thomas Cluzeau, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|November 6, 2018
Treatment-free remission with first- and second-generation tyrosine kinase inhibitorsJorge Cortes, Delphine Rea, Jeffrey H Lipton
European Journal of Haematology|May 7, 2014
Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcomeTristan Mirault, Delphine Rea, Arshid Azarine, et al.
Methods in Molecular Medicine|December 9, 2004
Adenoviral transduction of dendritic cellsRienk Offringa, Kitty Kwappenberg, Martijn Rabelink, et al.
Current Hematologic Malignancy Reports|March 14, 2012
Curing chronic myeloid leukemiaDelphine Rea, Philippe Rousselot, Joelle Guilhot, et al.
Current Hematologic Malignancy Reports|February 23, 2024
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New DirectionsDelphine Rea, Sofiane Fodil, Etienne Lengline, et al.
Lancet (London, England)|September 2, 2008
Dasatinib-induced lupusDelphine Rea, Anne Bergeron, Claire Fieschi, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 13, 2023
Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid LeukemiaSimone E Dekker, Delphine Rea, Jean-Michel Cayuela, et al.
Blood|December 20, 2014
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsPeter Valent, Emir Hadzijusufovic, Gerit-Holger Schernthaner, et al.
Leukemia Research|February 28, 2012
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemiaAdam Gater, Louise Heron, Linda Abetz-Webb, et al.
Haematologica|March 25, 2014
Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemiaDelphine Rea, Tristan Mirault, Thomas Cluzeau, et al.
Pageof 11